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Abstract 
Interleukin-1/3 (IL-1/3) increased the production of cyclic AMP and prostaglandin E 2 (PGE 2) by cultured human decidual cells during 
24 h of stimulation, but not over short incubation times (< 6 h). At concentrations of IL-1/3 ranging from 1 to 100 pg/ml, there were 
parallel changes in cyclic AMP and PGE 2 levels, but 1000 pg of IL-1/3/ml inhibited cyclic AMP production while still stimulating PGE 2 
synthesis. The possible link between cyclic AMP and PGE 2 was therefore studied further. Inhibition of IL-1/3-stimulated PGE 2 synthesis 
by indomethacin and direct addition of PGE 2 had no effect on cyclic AMP levels, indicating that PGE 2 did not increase cyclic AMP 
production by human decidual cells and confirming the independent synthesis of cyclic AMP and PGE 2. The increase in cyclic AMP 
production induced by IL-1/3 is dependent on protein synthesis, but it is not known which component of the adenylate cyclase is 
increased. A phosphodiesterase inhibitor potentiated the effects of IL-l/3 on cyclic AMP synthesis, indicating that the cytokine may 
increase cyclic AMP metabolism. We suggest that high concentrations of IL-1/3 activate phosphodiesterase activity more than adenylate 
cyclase, which gives rise to the low levels of cyclic AMP noted above. IL- 1/3 also decreased forskolin-stimulated cyclic AMP production, 
which again indicates increased cyclic AMP metabolism. Since most concentrations of IL-1/3 alone increased cyclic AMP levels, this 
stimulation must out-weigh the increase in metabolism apparent in the presence of forskolin, phosphodiesterase inhibitor or high levels of 
interleukin. It is clear that IL-l/3 increased ecidual PGE 2 production independently of cyclic AMP, and that other second messenger 
must mediate the action of this cytokine. 
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1. Introduction 
Preterm birth has been identified as the primary cause 
of perinatal mortality and morbidity [1]. The initiating 
events in preterm labour are not well characterised, al- 
though in women with intrauterine infections increased 
levels of prostaglandins [2] and interleukins [3-6] are 
present in amniotic fluid before delivery. Prostaglandin E 2 
(PGE 2) causes cervical ripening and dilatation [7], while 
PGF 2 a is thought o co-ordinate myometrial contractions 
leading to delivery of the infant [8]. A number of intra- 
uterine tissues can produce prostaglandins, including am- 
nion, chorion and decidua [9], but a number of studies 
have strongly suggested that the decidua is the most 
important source of prostaglandins in labour [10-12]. This 
is consistent with studies showing that the decidua con- 
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tains macrophages [13] and releases cytokines [14-16] 
which can activate decidual prostaglandin production [17] 
and hence cause labour. Known regulators of decidual 
prostaglandin synthesis include IL- 1 a [ 17], IL- 1 fl [ 17,18], 
IL-6 [19] and TNF-a [14], but the intracellular mecha- 
nisms underlying the cytokine stimulated increases in de- 
cidual prostaglandin production are not known. 
IL- 1 fl stimulates prostaglandin production by other cell 
types [20], but again the second messenger systems mediat- 
ing the effects of IL- 1/3 are not fully known. Some studies 
have implicated protein kinase A (cyclic AMP-dependent) 
[21] or protein kinase C [22] in the mechanism of action of 
IL-1/3, and at least two novel kinases may also be in- 
volved [23]. An active adenylate cyclase system is present 
in human third trimester decidual cells [24-27]. Some 
studies indicate that increases in cyclic AMP production 
are linked to increased ecidual prostaglandin production 
[24-26], but this is not a general finding [27]. The aim of 
this study was to establish whether IL-1/3 increased the 
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Table 1 
Effects of IL-1/3 and forskolin on cyclic AMP production by human 
decidual cells 
Time Intracellular cyclic AMP 
(pmol/106 cells) 
Extracellular cyclic AMP 
(pmol/10 6cells) 
control IL- 1/3 control IL- 1/3 
5min 8.7±0.4 12.3±1.7 1.6±0.1 1.0±0.2 
15min 15.1±6.3 25.9±9.2 1.3±0.2 1.0±0.2 
30min 12.6±5.2 16.3±0.8 1.0±0.2 1.1±0.2 
60 ~n 31.3±15.7 14.7±7.8 1.3±0.1 1.3±0.1 
Con~ol Forskolin Control Forskolin 
5min 2.0±0.1 269.8±33.5* 5.1±1.1 10.7±4.2 
Stimulation f intracellular nd extracellular cyclic AMP levels by IL-1/3 
(100 pg/ml) or forskolin (10 /xM). All data are means+S.E. (n = 3), 
and are typical of three xperiments. * : P < 0.01 compared with control 
cyclic AMP level. 
production of cyclic AMP by cultured third trimester 
human decidual cells, and also to find whether there was a 
link between IL-1/3-stimulated changes in cyclic AMP 
levels and the production of prostaglandins. Previous work 
has shown that the production PGE 2 parallels that of 
PGE 2 c~ in human decidual cells [18], so in this study we 
measured PGE 2 alone on the basis that this would be 
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Fig. 1. Third trimester decidual cells were cultured with (hatched bar) or 
without (D) IL-1/3 at 100 pg/ml for the periods hown, and the 
biosynthesis of PGE 2 (a) or cyclic AMP (b) were determined. All data 
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Fig. 2. Third trimester decidual cells were cultured with different concen- 
trations of IL-1/3 as shown for 24 h. The production of PGE z (a) and 
cyclic AMP (b) were determined. All data are means-I- S.E. (n = 3) and 
are typical of four experiments. 
2. Materials and methods 
Human fetal membranes were obtained after delivery of 
normal term infants by caesarean section, and decidual 
cells were prepared as described previously by a two-stage 
enzyme digestion [28]. The cells were plated at a concen- 
tration of 250 000/ml  and cultured in Medium 199 + 10% 
fetal calf serum with 2 mM glutamine and 0.1% 
penicillin-streptomycin (all reagents from Sigma) at 37°C 
in 95% air: 5% CO 2. The cells were incubated for 24 h to 
allow recovery from the preparative procedures used, after 
which fresh medium containing different concentrations of 
IL-1/3 (British Biotechnology) were added to the cells for 
periods ranging from 5 min to 24 h. In some studies 
isobutyl-methylxanthine (IBMX) (Sigma) was included 
(0.3 mM) in the medium to inhibit phosphodiesterase 
activity and allow measurement of total cyclic AMP bio- 
synthesis, or forskolin (Sigma) was included to directly 
activate the adenylate cyclase. The medium was removed 
from the cells at the end of the incubation period and 
frozen at -20°C until assay for PGE 2 or cyclic AMP by 
commercial ELISAs (Amersham International). Intra- 
cellular cyclic AMP was extracted by the method of Lakey 
et al. [29]. The cells were rinsed with phosphate-buffered 
saline, and 1 ml ice-cold 80% ethanol added to each well. 
The cells were scraped off and transferred to Eppendorf 
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Table 2 
Effects of cycloheximide on extracellular cyclic AMP levels in the 
presence or absence of IL-1/3 
Cyclo~ximide E~racellularcycl icAMP(pmol/106cells) 
(~M)  con~ol +~-1 /3  
0 11.95:0.1 18.5±1.9" 
1.0 7.8±0.4 8.2±0.5 
10.0 6.0±1.4 8.0±0.6 
Data are means ± S.E. (n = 3) and are representative of two experiments. 
* : P<0.01  vs. no IL-1/3. 
Table 3 
Effects of IL-lf l and IBMX (0.3 raM) on decidual extracellular cyclic 
AMP production 
IL- 1/3 (pg/ml) Cyclic AMP (pmol/106 cells/24 h) 
- IBMX + IBMX 
0 9.05:1.0 53.2±2.8 
1 13.25:1.6 66.05:0.4 
10 38.0±2.0 78.7±6.6 
1~ 43.35:7.9 118.75:11.6 
All data are means 5: S.E. (n = 3) and are representative of three experi- 
ments. 
tubes, and the wells washed again with 1 ml ethanol as 
above. The samples were combined and centrifuged at 
800 × g for 10 rain at 4°C. The supernatant was decanted 
and the pellet washed with 1 ml ethanol with further 
centrifugation. The supernatants were combined, 
lyophilised and reconstituted in 250 /xl distilled water 
before assay as above. All data were normalised to 106 
cells to permit comparison between different experiments. 
Data are shown as means ,  S.E. unless otherwise stated 
were compared using analysis of variance (ANOVA). Cell 
preparations from a total of 17 pregnancies were used in 
these studies. Each cell preparation was cultured sepa- 
rately, and each experiment was repeated with a minimum 
of three different preparations. Basal synthesis of PGE 2 
and cyclic AMP varied between patients, although the 
positive effects of IL-1/3 were consistent; his variation 
meant that data from different individuals could not be 
combined, and representative data are therefore shown. 
3. Results 
Short term incubation of human decidual ceils with 
IL-1/3 at 100 pg/ml had no effect on intracellular or 
extracellular cyclic AMP levels (Table 1). It might be 
argued that the adenylate cyclase enzyme was defective in 
these cell preparations, but incubation with forskolin indi- 
cated that an active adenylate cyclase was present as 
indicated by increased intracellular levels of cyclic AMP 
within 5 min (Table 1). During longer incubations IL-1/3 
increased the synthesis of PGE 2 by human third trimester 
decidual cells (Fig. la) up to 24 h of culture, and this was 
paralleled by an increase m cyclic AMP synthesis (Fig. 
lb). The optimum stimulatory concentration f IL-1/3 was 
100 pg/ml for both cyclic AMP and PGE 2 over 24 h of 
stimulation (Fig. 2), but 1000 pg/ml of IL-1/3 increased 
PGE 2 production while inhibiting cyclic AMP levels. The 
reasons for this will be addressed in the discussion. 
The parallel increases in cyclic AMP and PGE 2 in the 
presence of IL-1/3 at concentrations in the range 1-100 
pg/ml implied that there might be a functional ink be- 
tween these changes. It was considered possible that the 
increase in cyclic AMP induced by IL-1/3 was the result 
of increased PGE 2 production, so cells were stimulated 
with IL-1/3 in the presence and absence of indomethacin 
(30 /zM). IL-1/3-stimulated cyclic AMP production (net 
increase 5.9 + 1.7 pmol/106 cells/24 h) was unaffected 
by indomethacin (net increase 6 .2_  1.7 pmol/106 
cells/24 h), whereas IL-lfl-stimulated PGE 2 production 
was inhibited by over 90% (net increases 3.9 + 0.6 ng/106 
cells/24 h with 100 pg IL-1/3/ml, 0.13_ 0.02 ng/106 
cells/24 h with IL-1/3 and 30 /zM indomethacin). These 
data indicate that cyclic AMP production was independent 
of PGE 2 synthesis. The addition of PGE 2 at concentrations 
from 10 -9  to 10 -6  M was also without effect on cyclic 
AMP levels (results not shown). 
The long incubation time required for IL- 1/3 to increase 
cyclic AMP synthesis suggested that protein synthesis 
might be required, and cycloheximide was found to inhibit 
the effects of IL-1/3 on cyclic AMP synthesis (Table 2). 
Basal cyclic AMP levels were also decreased. These stud- 
ies did not reveal whether the increase in cyclic AMP was 
due to increased synthesis, decreased metabolism or a 
combination of them. The phosphodiesterase inhibitor 
isobutyl methylxanthine (IBMX) potentiated the effects of 
Table 4 
Effects of IL-1/3 (100 pg/ml)  and forskolin on decidual extracellular cyclic AMP and prostaglandin E 2 production 
Forskolin (~M)  Cyclic AMP (pmol/106 cells/24 h) PGE 2 (ng/106 cells/24 h) 
- IL-1/3 +IL-1/3 - IL-1/3 +IL-1/3 
0 14.2 + 0.8 29.9 5:1.3 * 0.24 5:0.02 4.72 5:0.43 
0.1 32.7 5:0.5 27.4 5:1.0 * 0.21 5:0.02 4.47 5:0.03 
1.0 ,155.1 5:1.2 356.3 5:5.4 * 0.18 5:0.01 3.83 5:0.11 
10.0 592.4 5:0.3 555.3 5:15.2 * 0.16 5:0.03 3.38 5:0.40 
All data are means 5: S.E. (n = 3), and are representative of three experiments. * : P < 0.05 vs. forskolin alone. 
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IL- 1/3 (Table 3), which indicates that the cytokine acceler- 
ated degradation of cyclic AMP as well as increasing 
synthesis. Decidual cells were co-stimulated with IL-1/3 
and forskolin to determine whether there was a more 
complex interaction whereby changes in cyclic AMP syn- 
thesis could affect IL-1/3-stimulated PGE 2 production. 
Forskolin did not affect PGE 2 synthesis in the presence or 
absence of IL-1/3 (Table 4), which is consistent with 
previous observations [27]. IL-1/3 increased basal cyclic 
AMP levels as would be expected from the previous data, 
and decreased forskolin-stimulated cyclic AMP synthesis 
(Table 4), which was consistent with accelerated 
metabolism of cyclic AMP. Analogues of cyclic AMP 
(dibutyryl cyclic AMP or 8-bromo-cyclic AMP) were 
without effect on basal and IL-1/3-stimulated PGE 2 pro- 
duction (results not shown). 
4. Discussion 
The stimulation of cyclic AMP production by 1L-1/3 
from human decidual cells has not previously been re- 
ported, although the increased production of PGE 2 is 
consistent with previous studies [17,18]. Although there 
was a strong correlation between the effects of IL-1/3 on 
PGE 2 and cyclic AMP levels, direct stimulation of adeny- 
late cyclase with forskolin does not affect PGE 2 produc- 
tion [27]. This shows that there was not a functional ink 
between cyclic AMP and PGE 2 production, although it is 
clear that both are regulated by IL-1/3. The increase in 
cyclic AMP levels was not the result of increased PGE 2 
synthesis, since inhibition of PGE 2 production with indo- 
methacin and direct addition of PGE 2 had no effect on 
cyclic AMP levels. This lack of interaction between PGE 2 
and cyclic AMP differs from data obtained from rat uteri 
which indicates that PGE 2 can increase cyclic AMP levels 
[30,31], but another study indicated that a PGE 2 analogue 
(sulprostone) administered in vivo may directly inhibit 
adenylate cyclase in first trimester human decidua [32]. 
The differences between rats and humans, and also be- 
tween endometrium and decidua, probably account for the 
differences observed in these studies. It might be argued 
that intracellular PGE 2 regulates cyclic AMP production 
through receptors not accessible to the added PGE 2, but 
this seems unlikely on two grounds. Firstly, the literature 
on PGE 2 receptors indicates that they are generally cell- 
surface proteins [33], and while an intracellular PGE 2 
receptor/binding protein has been identified in rat kidney 
cells [34], it is much smaller (at 16 kDa) than the func- 
tional PGE 2 receptors cloned and sequenced recently which 
are about 50 kDa [35] and is therefore likely to be a 
binding protein rather than a signal-transducing receptor. 
Secondly, it has been shown that decidual cells readily 
metabolise PGE 2 [36], which suggests that there is no 
barrier to the entry of this prostaglandin to decidual cells. 
The simplest interpretation of the data is that IL-1/3 acti- 
vated at least two second messenger systems in decidual 
cells, namely adenylate cyclase and a still undefined mech- 
anism which leads to PGE 2 synthesis. This may be perti- 
nent to the controversy as to the role of cyclic AMP in the 
effects of IL-1/3 [37,38]; our results show that while IL-1/3 
can increase the production of cyclic AMP, this second 
messenger does not necessarily mediate all the effects of 
IL-1/3. 
Combining IL-1/3 and forskolin indicated that there 
was a complex interaction between these effectors at the 
level of cyclic AMP. Individually they increased cyclic 
AMP levels, but the combination had less effect on cyclic 
AMP synthesis than would be predicted by simple addition 
(Table 4). This might be explained by increased metabolism 
of cyclic AMP, which is consistent with the synergistic 
effects of IL-I/3 and IBMX (Table 3). A hormone-media- 
ted increase in phosphodiesterase enzyme has been re- 
ported in rat testis Leydig cells [39], giving rise to similar 
decreases in cyclic AMP levels. This increase in 
metabolism must be less than the net increase in cyclic 
AMP synthesis by IL-113 levels ranging up to 100 pg/ml,  
otherwise the data obtained with IL-1/3 alone do not make 
sense. The very low levels of cyclic AMP found in the 
presence of 1000 pg IL-1/3/ml (Fig. 2) are consistent with 
an activation or increased synthesis of cyclic AMP phos- 
phodiesterase uggested above, such that at this high level 
of cytokine the rate of cyclic AMP metabolism exceeds the 
rate of production. Direct studies are required to identify 
the components of the adenylate cyclase which are synthe- 
sised in response to IL-1/3 and to confirm the increase in 
phosphodiesterase enzyme, but these fall outside the scope 
of this report. 
These data contradict the findings of Warrick et al. [24], 
Hassan et al. [25] and Mitchell et a1.[26]. In these studies, 
forskolin, cholera toxin and dibutyryl cyclic AMP in- 
creased prostaglandin synthesis, and IBMX increased these 
effects; isoproteronol, salbutamol and epinephrine also in- 
creased the synthesis of PGE 2 and PGF 2 a by cultured 
human third trimester decidual cells [24,25]. Dibutyryl 
cyclic AMP potentiated IL-1/3-stimulated PGE 2 synthesis 
[26], which disagrees with our data. Careful comparison of 
the experimental details reveals some differences in the 
systems used. All our studies were done on cells obtained 
prior to labour and cultured for no more than 48 h, 
whereas Warrick et al. [24] used cells obtained after nor- 
mal labour, and Hassan et al. [25] and Mitchell et al. [26] 
used cells obtained before labour and cultured them for 
4-7 days before initiating any experiments. Decidual 
prostaglandin synthesis is increased by labour [12], but the 
reasons for this increase have not been established. It is 
possible that changes in the coupling between receptors 
and second messenger systems occur in labour, and this 
may explain the data obtained by Warrick et al. [24] which 
showed a functional ink between /3-adrenergic factors, 
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cyclic AMP synthesis and prostaglandin production. 
Changes in decidual cell biochemistry with increasing 
periods of culture show in l~he responses to a protein kinase 
C activator, phorbol myristate acetate (PMA). After 2 -3  
days of culture PMA increased ecidual cell prostaglandin 
synthesis [40,41], but Hassan et al. [25] showed no effect 
of PMA on decidual PGE 2 synthesis after 4 -7  days of 
culture. This does not apply to the data of Mitchell et al. 
[26], in that their cells retained the response to PMA. It is 
apparent hat more detailed studies on the role of cyclic 
AMP in decidual PGE 2 synthesis are needed before a full 
understanding is achieved. 
PGE 2 has been clearly implicated in human labour [8], 
but the function of decidual cyclic AMP is not easily 
explained. It is known that vasodilators like prostacyclin 
decrease muscle contraction by increasing intracellular lev- 
els of cyclic AMP [42]. We suggest hat the increase in 
cyclic AMP may oppose the effects of decidual prosta- 
glandins, which would increase myometrial contractility 
leading to labour [8]. Low levels of IL- 1/3 would tend to 
increase PGE 2 and cyclic AMP levels, and maintain a 
balance between factors encouraging and retarding pro- 
gression to labour. It is known that many cytokines are 
produced by fetal membrane tissue and that low levels are 
present in amniotic fluid before labour [3-6]. An increase 
in the levels of IL-1/3 for more than a few hours may 
change this balance, as it is clear that decidual cells can 
produce high levels of prostaglandins for many hours after 
labour [12]. The detailed processes of labour have not been 
established in man, so it is difficult to speculate further on 
the role of cyclic AMP. Many tissues may be involved in 
labour including myometrium, cervix, decidua (itself a 
complex tissue containing raany cell types [13,28]), chorion 
and amnion, and it is probable that cyclic AMP may 
regulate one of these. Further studies on this point are 
needed. As the decidua is. a complex tissue [13,28], we 
have not attempted to define the responsive population of 
cells. It is possible that mediators released from IL-1/3- 
stimulated cells affect cyclic AMP production in a differ- 
ent cell-type, but the parallel dose- and time-responses 
(Figs. 1 and 2) make this unlikely. 
In summary, we have shown that IL-1/3 increased the 
production of PGE 2 and cyclic AMP by cultured human 
decidual cells, but the increase in PGE 2 was not dependent 
on activation of adenylate cyclase. Protein kinase C also 
does not seem to mediate the effects of IL-1/3 on PGE 2 
production by decidual cells [41], but the functions of the 
novel protein kinases identified by Guesdon et al. [43] 
have not been investigated in human decidual cells. 
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